Nonetheless, since the study was not performed in patients with RA, and given that inflammation affects the expression of transporters and drug-metabolizing enzymes [24], the possibility of RA interfering with OCT expression, which is then corrected by tofacitinib, cannot be excluded. This evidence concerns the gene PLXNA2 and rheumatoid arthritis.